Four Criminal-Law Arrows at Once: How Can Pharmaceutical Executives "Drive Safely" Through the Storm?
Article images may contain Chinese text.

Weiming Penguin · Compliance Special Session
Seminar on Criminal Risk Management and Compliance in the
Pharmaceutical Industry June 24, Shanghai

In 2026, the compliance storm sweeping the pharmaceutical industry has been more intense than anyone anticipated. If you work in legal, compliance, or management at a pharmaceutical company, be sure to read the following in full—it concerns the boundaries of your personal liability under the new regulatory framework.




In 2026, pharmaceutical regulation in China has entered a period of intensive legislative activity. The Judicial Interpretation on Corruption and Bribery (II) issued by the Supreme People's Court and the Supreme People's Procuratorate took effect on May 1; the Measures for the Administration of Pharmaceutical Representatives will formally take effect on August 1; the Compliance Guidelines for Online Retail Sales of Prescription Drugs were introduced on May 25; and the State Administration for Market Regulation's Compliance Guidelines for Pharmaceutical Enterprises on Preventing Commercial Bribery Risks were formally implemented at the beginning of the year.
What does the combined impact of four major new rules mean? Kickback-driven sales, extracting funds through CSOs, violations of pharmaceutical representative registration requirements, and gray-area online drug sales—practices once tacitly accepted as "industry norms"—are now fully within range of criminal prosecution. It is no longer a question of "possibly being investigated," but of "facing prosecution at any time."



First: Where are the boundaries of your company's risk exposure? Under the new rules, which practices have already crossed the line? Which remain in a "gray area"—but could turn black at any moment?
Second: How is executives' personal liability determined? How do offenses committed by an entity differ from those committed by individuals? Can executives avoid liability by claiming they "did not know"? The answer may be harsher than you expect.
Third: Which existing practices must be corrected immediately? This is not a question of "whether to change," but of "failing to change today could mean trouble tomorrow."


Special Guests Dacheng Law Offices & Kangbai Hansen Deliver a Hard-Hitting, Hands-On Compliance Workshop

To help pharmaceutical management teams and compliance professionals develop a clear understanding of risk and practical response capabilities, Weiming Penguin is joining Beijing Dacheng Law Offices (Shanghai) and Beijing Kangbai Hansen Pharmaceutical Technology to host: 💼 Seminar on Criminal Risk Management and Compliance in the Pharmaceutical Industry
This is not a theoretical lecture full of generalities. It is a closed-door, hands-on workshop focused exclusively on candid discussion, concrete answers, and practical exercises.





PART 01 | The Criminal Risk Landscape in the Pharmaceutical Industry and Practical Responses to Criminal Investigations
1. Key insights into Interpretation (II) from China's Supreme People's Court and Supreme People's Procuratorate: conviction standards, sentencing changes, and industry impact
2. Criminal risks arising from kickback-driven sales, collecting prescriber-level prescription statistics, donations, and equipment placements
3. Risks involving extracting funds through CSOs, off-the-books funds, dual contracts with inconsistent terms, and funds flowing back to their source
4. New forms of concealed bribery, including cultivating personal relationships for improper benefit, dividends on shares granted without capital contribution, and deferred-benefit corruption
5. Connections and distinctions among individual offenses, offenses committed by entities, and criminal conduct by agents
6. A complete walkthrough of major real-world cases: gains and losses for companies and executives
7. How companies should cooperate with criminal investigations: what to get right and what to avoid
8. Live role-play: facing an investigation by China's public security authorities

PART 02 | The New Measures for the Administration of Pharmaceutical Representatives—Compliance Requirements and Risk Controls
1. Understanding the key changes: major adjustments from the trial measures to formal implementation
2. Defining the boundaries of pharmaceutical representatives' sole lawful function: separating scientific promotion from sales activities
3. The list of nine prohibited activities: a point-by-point analysis of red lines, including collecting prescriber-level prescription statistics and taking on sales targets
4. The full chain of MAH primary responsibilities: eligibility, registration, training, and accountability for violations
5. Look-through accountability in delegated CSO management: contractual provisions and ongoing monitoring mechanisms
6. Rebuilding performance evaluation systems: a compliant transition from sales-volume orientation to scientific value

PART 03 | Understanding Pharmaceutical Channel Risks and Promoting Business Growth & Compliance
First Half: End-to-End CSO Risks and Key Verification Points
1. Reshaping the CSO ecosystem and its core risk categories
2. Key points for end-to-end CSO verification: before, during, and after activities
3. Kangbai Hansen's end-to-end CSO verification framework and its value
Second Half: Weiming Penguin StarPlex—End-to-End Data to Promote Business Growth & Compliance
1. The StarPlex end-to-end data engine: from multimodal collection to decision support
2. Real-time monitoring with 36 risk Probes: building a proactive interception hub for compliance risk management
3. Proven in practice at leading pharmaceutical companies: retail outlet expansion efficiency ↑60%, operations and maintenance costs ↓70%

PART 04 | Compliance Guidelines for Online Retail Sales of Prescription Drugs—New Regulatory Requirements and Practical Implementation
1. Core requirements and regulatory rationale of the Compliance Guidelines for Online Retail Sales of Prescription Drugs
2. Real-name drug purchases, prescription review, and building an end-to-end traceability system
3. System compliance requirements for separating prescribing from dispensing and isolating diagnosis and treatment from sales
4. Compliance boundaries for AI-assisted prescription review: what is and is not permitted
5. Red lines on prohibited sales-oriented promotion, and compliance risks in short-form videos and livestreaming
6. The interplay between criminal risks and administrative liability in online drug sales channels




Chen Litong is a partner at Dacheng Law Offices, holds an LL.M. from New York University in the United States, is qualified as a lawyer in China and New York State, and serves as an arbitrator at the Hong Kong International Arbitration Centre. His practice covers the development of corporate compliance management systems, anti-bribery and anti-fraud investigations, ESG compliance, data compliance, criminal defense, and more. He currently serves as a member of China's National Technical Committee on Governance of Organizations Standardization; a registered expert representing China on ISO/TC 309, Governance of Organizations; chief compliance expert of the Compliance Working Committee of the China Entry-Exit Inspection and Quarantine Association; vice president of the International Risk and Compliance Association; and an independent director of ZTE Kangxun. He previously served as Asia-Pacific compliance director at Ford Motor Company and as a specially appointed compliance officer at Luckin Coffee. Chen has helped more than a hundred companies develop compliance management and anti-bribery management systems, and helped more than 30 companies obtain ISO 37301 compliance management system certification. He was selected for the Ministry of Justice's National List of 1,000 Lawyers with Expertise in Foreign-Related Legal Affairs and has appeared repeatedly in prominent rankings including Chambers, GRCD, The Legal 500, and LEGALBAND. He also received an ISO Excellence Award for his work developing ISO 37008, the technical guidance on internal investigations of organizations. His books include Commercial Bribery Risk Management; The Emergence, Prevention, and Control of Compliance Risks in Corporate Internationalization; Practice for Chief Compliance Officers and Corporate Compliance Professionals; and 60 Questions on Hot Topics in Corporate Compliance Management.

Xu Dan (Viola), a senior pharmaceutical industry solutions expert at Weiming Penguin, focuses on digital transformation in the pharmaceutical and healthcare industries. She has experience providing full-lifecycle services to leading companies across chemical drugs, traditional Chinese medicines, health supplements, and biologics. Her clients include industry leaders such as Bayer, Waters, Santen, GSK, KUNPHARM Group, BYHEALTH, Hisun Pharmaceutical, and Tasly Group.
With extensive experience in pharmaceutical distribution, sales management, and channel digitalization, she has a thorough understanding of end-to-end pharmaceutical business models, including distribution, sales to retail outlets, distributor recruitment and sell-through, distribution flow traceability, expense control, and sales forecasting. She accurately identifies companies' core pain points in IT development, data governance, channel compliance, and marketing efficiency.
She excels at connecting business needs with practical applications of big data and AI, tailoring integrated digital solutions to each company's development stage, regulatory compliance requirements, and channel conditions. Her implemented projects span channel data platforms, retail outlet insights, intelligent sales forecasting, and end-to-end risk alerts, using data to help pharmaceutical companies reduce costs and improve efficiency, manage channels with greater precision, and achieve sustainable business growth.

Xu Jie (Leo), an enterprise risk management expert and director of consulting at Kangbai Hansen, previously worked at a number of domestic, foreign-invested, and publicly listed companies, helping improve commercial operations, optimize channels, recruit distributors for new products, and secure market access. Since joining Kangbai Hansen in 2016, he has provided channel and corporate compliance risk verification, management optimization, and healthcare consulting services to numerous well-known Chinese and international companies in pharmaceuticals, medical devices, and the broader healthcare sector.

Lin Shengda is a lawyer at Dacheng's Shanghai office and formerly deputy legal director at a prominent Chinese fintech unicorn group. He holds an LL.M. from Columbia University and an LL.B. from East China University of Political Science and Law. His practice focuses on anti-bribery and anti-fraud compliance, data privacy compliance, economic sanctions and trade control compliance, and compliance management in the pharmaceutical and healthcare industries. He previously served concurrently as Greater China compliance manager for a U.S.-invested company engaged in pharmaceutical and medical device manufacturing, R&D, and sales, helping it strengthen its Greater China compliance management system and undertake compliance activities to meet the requirements of China's Measures for the Administration of Pharmaceutical Representative Registration (Trial). He has also provided compliance legal services, including the development of anti-corruption and data and privacy compliance management systems, to numerous leading Chinese and international companies engaged in pharmaceutical and medical device manufacturing, R&D, and sales, as well as to a prominent Chinese CSO client.
Representative clients include, but are not limited to, Ctrip, Douyin, Qunar, UnionPay, KE Holdings, Xiaohongshu, Fosun Group, Estée Lauder, LVMH, and Lululemon. He has also helped a fintech unicorn establish its compliance management system.



Date and time: Wednesday, June 24, 2026, 14:30–17:00 (check-in at 14:00) Venue: Beijing Dacheng Law Offices (Shanghai) | Training Room, 24th Floor, Shanghai World Financial Center, 100 Century Avenue, Pudong, Shanghai Format: Small-group, in-person session combining case discussions with live Q&A Who should attend: Heads of corporate legal, compliance, internal audit, and government affairs; sales and marketing management; corporate executives



This in-person seminar will also be livestreamed online. In-person and online places are limited. Please scan the QR code below to register.
Contact phone: 13717915751

Criminal law makes no allowance for personal connections, and compliance is no matter of luck. Before the storm arrives, taking a seat in this classroom could be the most worthwhile investment you make this year.
Organizer
Beijing Dacheng Law Offices (Shanghai)
Co-organizer
Weiming Penguin (Beijing) Technology Co., Ltd.
Beijing Kangbai Hansen Pharmaceutical Technology Consulting Co., Ltd.
